SSY Group(02005.HK): Two APIs Approved by NMPA for Marketing
NewTimeSpace News: SSY Group Limited (02005.HK) issued a voluntary announcement on February 27, 2026, stating that the Group’s metoclopramide and metoclopramide hydrochloride have been approved by the National Medical Products Administration (NMPA) for registration as APIs for use in marketed finished dosage forms.
These two APIs are dopamine D2 receptor antagonists and also act as 5-hydroxytryptamine 4 (5-HT4) receptor agonists, which promote gastrointestinal motility. They are primarily used for anti-emesis and the treatment of nausea, belching, abdominal distension, reflux esophagitis, and other related conditions.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Trustee Purchases 900,000 Shares for Approximately HKD 2,414,700 under Restricted Share Award Scheme
- SSY GROUP (02005.HK): Gadobutrol injection and indocyanine green for injection approved, enhancing imaging and critical care product portfolio
- SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
- SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage
- SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
